Results 131 to 140 of about 20,527 (318)
Is Dupilumab an Immunosuppressant?
Journal of Drugs in Dermatology, 2020 Matthew J. Zirwas +2 more
openaire +2 more sources
Vitiligo during dupilumab therapy
JAAD Case Reports, 2023 Picone, Vincenzo +4 more
openaire +5 more sources
Clinical Case ReportsThe off‐label use of dupilumab has proven to be an effective treatment option for severe chronic actinic dermatitis (CAD). We present the first case of CAD presenting with dupilumab‐induced erythrodermic psoriasiform dermatitis.
Joe Khodeir, Maya Habre
doaj +1 more source
A comprehensive analysis on the safety of two biologics dupilumab and omalizumab
Frontiers in MedicineDupilumab was approved for the treatment of several dermatologic immune-mediated inflammatory diseases, such as atopic dermatitis and bullous pemphigoid; whereas omalizumab is the first biological agent which was approved to treat chronic spontaneous ...
Yu Xiao, Wanying Yang, Muyang Wang
doaj +1 more source
Two phase 3 trials of Dupilumab versus placebo in atopic dermatitis [PDF]
, 2017 Dahdah, Lamia +2 more
core +1 more source
Two atopic dermatitis patients in whom dupilumab improved aberrant epidermal protease activities [PDF]
, 2019 Hayato Nomura +3 more
openalex +1 more source
Dupilumab for Chronic Eosinophilic Pneumonia [PDF]
Pediatric Pulmonology, 2020 Christopher Fowler, Wynton Hoover
openaire +3 more sources
Clinical &Experimental Allergy, EarlyView.Chronic spontaneous urticaria (CSU) is a debilitating skin disorder with significant impact upon quality of life. Current guidelines advocate stepwise treatment of standard dose antihistamines, high dose antihistamines, omalizumab and ciclosporin.
Katie Ridge +7 more
wiley +1 more source
Respiratory Medicine Case ReportsDupilumab is a monoclonal antibody that has recently been introduced for the treatment of asthma. It has the potential to significantly alter the progression and severity of T2 -dependent diseases, including severe asthma.
Agnieszka Gawlewicz-Mroczka +4 more
doaj